Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer

08 December 2023: Clinical Research

Wei Tao ^1DEF* , Weiqi Wang ^1CDF , Jingfang Zhai ^2BCF , Linlin Guo ^1ABF

DOI: 10.12659/MSM.940545

Med Sci Monit 2023; 29:e940545

Table 5 Parameters of patients responsible for the insensitive response of neoadjuvant chemotherapies.

Parameters	Odd ratio	95% Cl	P value
Age (≤40 years vs >40 years)^*	1.1231	1.0123–1.2341	0.0411
Hemoglobin (≤9.5 g/dL vs >9.5 g/dL)^*	1.5123	1.4221–1.6231	0.0452
Platelet ((≤300×10)/L vs >(300×10)/L)^*	1.5221	1.4581–1.6214	0.0481
Body mass index (≤23.5 kg/m vs >23.5 kg/m)	1.2211	1.1458–1.3211	0.0492
Tumor size (≤5 cm vs >5 cm)^*	2.4312	2.0412–2.6211	0.0321
FIGO stage (IIA2 vs IB3)^*	2.2133	2.0147–2.5142	0.0335
Multivariate analysis. FIGO – The International Federation of Gynecology and Obstetrics; IB3 – larger than 4 cm; IIA2 – spread from the cervix to the upper two-thirds of the vagina; Cl – confidence interval. ^* Parameter responsible for insensitive response to neoadjuvant chemotherapies. All results were considered significant if the value was less than 0.05 and the odds ratio was more than 1.